- 作者：Gary Shienbaum ; Carlos Alexandre A. Garcia Filho ; Harry W. Flynn Jr. ; hflynn@med.miami.edu ; Renata Portella Nunes ; William E. Smiddy ; Philip J. Rosenfeld
- 刊名：American Journal of Ophthalmology
- 出版年：2013
- 出版时间：June, 2013
- 年：2013
- 卷：155
- 期：6
- 页码：1009-1013
- 全文大小：1828 K
Purpose
To report the visual and anatomic outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy in the management of marked submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD).Design
Retrospective, interventional, consecutive case series.
Methods
Nineteen eyes of 18 patients with neovascular AMD and fovea involving submacular hemorrhage comprising greater than 50 % of the lesion area were treated with anti-VEGF monotherapy. Main outcome measures included mean visual acuity change from baseline, mean central lesion thickness change from baseline, mean number of injections at 6?months, and adverse events. Snellen visual acuity was converted to approximate ETDRS letter score for the purpose of statistical analysis.
Results
The mean change in approximate ETDRS letter score from baseline was?+12 letters at 3?months (P?= .003),?+18 letters at 6?months (P?= .001), and?+17 letters at 12?months follow-up (P?= .02). Seven eyes received ranibizumab, 6 eyes received bevacizumab, and 6 eyes received both at various time points. The mean number of injections at 6?months was 4.7. The mean OCT central lesion thickness decreased from 755?¦Ìm to 349?¦Ìm at 6?months follow-up (P?= .0008).
Conclusions
Management with anti-VEGF monotherapy may yield visual and anatomic improvements in eyes with marked submacular hemorrhage secondary to neovascular AMD.